CN105708838A - Conjunctivitis treatment drug - Google Patents
Conjunctivitis treatment drug Download PDFInfo
- Publication number
- CN105708838A CN105708838A CN201410722097.7A CN201410722097A CN105708838A CN 105708838 A CN105708838 A CN 105708838A CN 201410722097 A CN201410722097 A CN 201410722097A CN 105708838 A CN105708838 A CN 105708838A
- Authority
- CN
- China
- Prior art keywords
- conjunctivitis
- treatment drug
- conjunctivitis treatment
- vitamin
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A conjunctivitis treatment drug includes 1 mg of naphazoline hydrochloride, 1 mg of methyl sulfate neostigmine, 1 mg of dipotassium glycyrrhizinate, 1 mg of chlorpheniramine maleate, 1 mg of potassium aspartate and 1mg of vitamin B6. The conjunctivitis treatment drug has the advantages of quickly curing conjunctivitis and nourishing eyes.
Description
Technical field:
The invention belongs to field of pharmaceutical technology, particularly to a kind of medicine for treating conjunctivitis.
Background technology:
Conjunctivitis is kind of a commonly encountered diseases, and Common drugs effect is bad.
Summary of the invention:
The present invention is directed to the deficiencies in the prior art, it is provided that a kind of medicine for treating conjunctivitis.
This medicine includes: hydrochloric acid how first azoles woods 1mg, neostigmine methylsulfate 1mg, glycyrrhizic acid dipotassium 1mg, chlorphenamine maleate 1mg, aspartic acid 1mg, vitamin B6 1mg.
Advantages of the present invention: treat rapidly conjunctivitis, eye-protecting.
Detailed description of the invention:
The present invention is illustrated with the following examples:
This medicine includes: hydrochloric acid how first azoles woods 1mg, neostigmine methylsulfate 1mg, glycyrrhizic acid dipotassium 1mg, chlorphenamine maleate 1mg, aspartic acid 1mg, vitamin B6 1mg.
Advantages of the present invention: treat rapidly conjunctivitis, eye-protecting.
Claims (1)
1. one kind for treating the medicine of conjunctivitis, it is characterised in that: this medicine includes: hydrochloric acid how first azoles woods 1mg, neostigmine methylsulfate 1mg, glycyrrhizic acid dipotassium 1mg, chlorphenamine maleate 1mg, aspartic acid 1mg, vitamin B6 1mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410722097.7A CN105708838A (en) | 2014-12-03 | 2014-12-03 | Conjunctivitis treatment drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410722097.7A CN105708838A (en) | 2014-12-03 | 2014-12-03 | Conjunctivitis treatment drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105708838A true CN105708838A (en) | 2016-06-29 |
Family
ID=56146535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410722097.7A Pending CN105708838A (en) | 2014-12-03 | 2014-12-03 | Conjunctivitis treatment drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105708838A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389420B2 (en) | 2017-07-25 | 2022-07-19 | Das-Mg, Inc. | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis |
-
2014
- 2014-12-03 CN CN201410722097.7A patent/CN105708838A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389420B2 (en) | 2017-07-25 | 2022-07-19 | Das-Mg, Inc. | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
| WO2015121348A3 (en) | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor | |
| WO2014134225A3 (en) | Formulations comprising nutritive polypeptides and methods for treating cachexia, sarcopenia and muscle atrophy | |
| WO2017136795A8 (en) | Bacteria engineered to treat diseases associated with tryptophan metabolism | |
| EA201300669A1 (en) | SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION | |
| MX2016010179A (en) | Donepezil compositions and method of treating alzheimer's disease. | |
| WO2016207090A3 (en) | Targeted conjugates of ksp inhibitors | |
| WO2016200614A3 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| EP3565607A4 (en) | Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment | |
| MX2017009417A (en) | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof. | |
| WO2017022962A8 (en) | Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient | |
| PH12017502155A1 (en) | Formation of cyclosporin a/cyclodextrin nanoparticles | |
| MX2014001393A (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one. | |
| EP4039247A3 (en) | Sublingual formulation of riluzole | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| WO2016057413A3 (en) | Inhibitors of lysine gingipain | |
| MX2017007054A (en) | Compositions and methods of using modified release solabegron for lower urinary tract symptoms. | |
| CA3010981A1 (en) | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers | |
| WO2012017435A3 (en) | Soybean extracts for the treatment of hepatic disorders | |
| WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| WO2017070689A3 (en) | Solabegron zwitterion and uses thereof | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| CN105708838A (en) | Conjunctivitis treatment drug | |
| WO2014006571A3 (en) | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160629 |
|
| WD01 | Invention patent application deemed withdrawn after publication |